Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

2.0K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.7K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K
Infection01:20

Infection

14.4K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
14.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis.

Clinical and translational science·2025
Same author

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation.

Blood advances·2025
Same author

Printable molecule-selective core-shell nanoparticles for wearable and implantable sensing.

Nature materials·2025
Same author

Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.

Journal of the American College of Clinical Pharmacy : JACCP·2024
Same author

Challenges with sirolimus experimental data to inform QSP model of post-transplantation cyclophosphamide regimens.

Clinical and translational science·2024
Same journal

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

Clinical pharmacology and therapeutics·2026
Same journal

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

Clinical pharmacology and therapeutics·2026
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Developing and Using Therapeutics for Emerging Infections.

Jeannine S McCune1, Kellie S Reynolds2

  • 1Department of Pharmacy, University of Washington, Seattle, Washington, USA.

Clinical Pharmacology and Therapeutics
|July 17, 2015
PubMed
Summary
This summary is machine-generated.

Emerging infectious diseases like measles and Ebola highlight the need for new therapies and public education. Pharmacokinetic/dynamic modeling is crucial for combating infections, but adherence challenges and drug resistance remain significant concerns.

More Related Videos

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.4K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Outbreaks of vaccine-preventable diseases (e.g., measles) and emerging pathogens (e.g., Ebola) underscore global interconnectedness.
  • The rise of infectious diseases necessitates advancements in therapeutic development and public health strategies.

Discussion:

  • Pharmacokinetic/dynamic (PK/PD) modeling has been instrumental in managing infections like HIV and Hepatitis C.
  • Therapeutic adherence is critical; poor adherence contributes to the development of multidrug-resistant tuberculosis (MDR-TB).

Key Insights:

  • The journal issue covers preclinical models, PK/PD, pharmacogenomics, clinical trials, and educational efforts for emerging infections.
  • PK/PD modeling significantly reduces morbidity and mortality in viral infections.
  • Multidrug-resistant tuberculosis (MDR-TB) is a growing threat exacerbated by poor treatment adherence.

Outlook:

  • Continued research into novel therapies and robust public education are essential for managing future outbreaks.
  • Addressing adherence challenges is paramount to preserving the efficacy of antimicrobial therapies.
  • Lessons learned from past epidemics must inform strategies against re-emerging infectious threats.